Chen Lisheng, Wang Ruilin, Liu Honghong, Wei Shizhang, Jing Manyi, Wang Min, Zhao Yanling
Department of Pharmacy, Fifth Medical Center, General Hospital of Chinese PLA, Beijing, China.
Department of Pharmacy, Hebei North University, Zhangjiakou, China.
Evid Based Complement Alternat Med. 2021 Feb 2;2021:6612653. doi: 10.1155/2021/6612653. eCollection 2021.
The systematic review was designed to evaluate the safety and efficacy of Qishen Yiqi dropping pill combined with conventional Western medicine in the treatment of chronic heart failure (CHF).
Relevant randomized controlled trials (RCTs) investigating the clinical efficacy of Qishen Yiqi dropping pill combined with conventional Western medicine in treating CHF were widely searched in electronic databases, including PubMed, Cochrane Library, EMBASE, CBM, CNKI, Read-show database, VIP database, and WanFang up to December 26, 2020. The methodological quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0. Meta-analysis was performed by using Review Manager 5.3.
Twenty-one RCTs ( = 2162) that met the criteria were included in the review for the assessment of methodological quality. Meta-analysis showed that compared with the conventional Western medicine (control group), Qishen Yiqi dropping pill combined with conventional Western medicine (experience group) significantly improved clinical efficiency, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), brain natriuretic peptide level (BNP), 6 min-walk distance (6-MWD), and adverse reactions.
Qishen Yiqi dropping pill combined with conventional Western medicine are better than conventional Western medicine alone to improve the indicators of patients with CHF, which provides a certain basis for the treatment of CHF.
本系统评价旨在评估芪参益气滴丸联合传统西药治疗慢性心力衰竭(CHF)的安全性和有效性。
在包括PubMed、Cochrane图书馆、EMBASE、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普资讯数据库、万方数据库在内的电子数据库中广泛检索截至2020年12月26日调查芪参益气滴丸联合传统西药治疗CHF临床疗效的相关随机对照试验(RCT)。根据Cochrane系统评价员手册5.0评估每个试验的方法学质量。使用RevMan 5.3进行Meta分析。
纳入21项符合标准的RCT(n = 2162)进行方法学质量评估。Meta分析显示,与传统西药(对照组)相比,芪参益气滴丸联合传统西药(试验组)显著提高了临床有效率、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、脑钠肽水平(BNP)、6分钟步行距离(6-MWD),并减少了不良反应。
芪参益气滴丸联合传统西药在改善CHF患者指标方面优于单纯传统西药,为CHF的治疗提供了一定依据。